Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 299, Issue 2, 2010, Pages

  Russell, James C ^a   Kelly, Sandra E ^a   Diane, Abdoulaye ^a   Wang, Ye ^a   Mangat, Rabban ^a   Novak, Susan ^a   Vine, Donna F ^a   Proctor, Spencer D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Apolipoprotein B48; Chylomicron overproduction; Glomerular sclerosis; Inflammation; Metabolic syndrome; Microalbuminuria; Plasminogen activator inhibitor 1

Indexed keywords

ACUTE PHASE PROTEIN; APOLIPOPROTEIN B48; CHOLESTEROL; CHYLOMICRON; GLUCOSE; HAPTOGLOBIN; INSULIN; INTESTINAL LIPID; MEMBRANE LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; RIMONABANT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FOOD INTAKE; GLOMERULOSCLEROSIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART MUSCLE ISCHEMIA; HYPERINSULINEMIA; INSULIN METABOLISM; INSULIN RESISTANCE; INTESTINE SECRETION; KIDNEY; KIDNEY FAILURE; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NONHUMAN; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RAT; RENOVASCULAR DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ANIMALS; BIOLOGICAL MARKERS; BLOOD VESSELS; BODY WEIGHT; DISEASE MODELS, ANIMAL; EATING; INFLAMMATION; INSULIN RESISTANCE; INTESTINES; KIDNEY DISEASES; KIDNEY GLOMERULUS; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MYOCARDIAL ISCHEMIA; PIPERIDINES; PREDIABETIC STATE; PYRAZOLES; RATS; RATS, MUTANT STRAINS; RECEPTORS, CANNABINOID; RENAL CIRCULATION; SCLEROSIS; THROMBOSIS;

EID: 77955625847     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00173.2010     Document Type: Article

References (66)

1. Absher PM, Schneider DJ, Baldor LC, Russell JC, Sobel BE. The retardation of vasculopathy induced by attenuation of insulin resistance in the corpulent JCR:LA-cp rat is reflected by decreased vascular smooth muscle cell proliferation in vivo. Atherosclerosis 143: 245-251, 1999.
2. Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, Tambascia M, Bouskela E. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics (Sao Paulo) 61: 433-440, 2006.
3. Bifulco M, Grimaldi C, Gazzerro P, Pisanti S, Santoro A. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol 71: 1445-1456, 2007.
4. Brindley DN, Russell JC. Animal models of insulin resistance and cardiovascular disease: some therapeutic approaches using the JCR:LA-cp rat. Diabetes Obes Metab 4: 1-10, 2002.
5. Carai MAM, Columbo G, Gessa GL. Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 77: 2339-2350, 2005.
6. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 143: 380-385, 2005.
7. Correale M, Brunetti ND, De Gennaro L, Di Biase M. Acute phase proteins in atherosclerosis (acute coronary syndrome). Cardiovasc Hematol Agents Med Chem 6: 272-277, 2008.
8. De Lean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235: E97-E102, 1978.
9. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334: 952-957, 1996.
10. DesPrés JP, Ross R, Boka G, Alméras N, Lemieux I; ADAGIO-Lipids Investigators. Effect of rimonabant on the high-triglyceride/low- HDL-cholesteroldyslipidemia, intrabdominal adiposity, and liver fat. The ADAGIO-Lipids Trial. Arterioscler Thromb Vasc Biol 29: 416-423, 2009.
11. Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, D'Agostino RB, Gaziano JM, Vasan RS. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation 116: 480-488, 2007.
12. Di Marzo V, Szallasi A. Rimonabant in rats with a metabolic syndrome: good news after the depression. Br J Pharmacol 154: 915-917, 2008.
13. Dragomir E, Simionsecu M. Monocyte chemoattractant protein-1-a major contributor to the inflammatory process associated with diabetes. Arch Physiol Biochem 112: 239-244, 2006.
14. Ferrario F, Rastaldi MP. Histopathological atlas of renal diseases: diabetic nephropathy. J Nephrol 19: 1-5, 2006.
15. Getty-Kaushik L, Richard AM, Deeney JT, Krawczyk S, Shirihai O, Corkey BE. The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets. Obesity (Silver Spring) 17: 1856-1860, 2009.
16. Hassanali Z, Ametaj BN, Field CJ, Proctor SD, Vine DF. Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat. Diabetes Obesity Metab 12: 139-147, 2010.
17. Hayashi T, Hirano T, Taira T, Tokuno A, Mori Y, Koba S, Adachi M. Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease. Atherosclerosis 197: 154-158, 2008.
18. Hegele RA, Zinman B, Hanley AJ, Harris SB, Barrett PH, Cao H. Genes, environment and Oji-Cree type 2 diabetes. Clin Biochem 36: 163-170, 2003.
19. 1 synergistically increase PAI-1 and decrease matrix degradation in rat mesangial and fibroblast cells. Am J Physiol Renal Physiol 294: F1287-F1295, 2008.
20. Huang Y, Noble NA. PAI-1 as a target in kidney disease. Curr Drug Targets 8: 1007-1015, 2007.
21. Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F, Petrosino S, Di Marzo V. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol 158: 451-461, 2009.
22. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 126: 21-38, 2010.
23. Janiak P, Poirier B, Bidouard JP, Carouvele C, Pierre F, Gouraud L, Barbosa I, Dedio J, Maffrand JP, Le Fur G, O'Connor S, Herbert JM. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int 72: 1345-1357, 2007.
24. ob mice. Int J Obes (Lond) 29: 183-187, 2005.
25. Mangat R, Su J, Scott PG, Russell JC, Vine DF, Proctor SD. Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome. Biochem Soc Trans 35: 477-481, 2007.
26. O'Brien SF, Russell JC, Davidge ST. Vascular wall dysfunction in JCR:LA-cp rats: effects of age and insulin resistance. Am J Physiol Cell Physiol 277: C987-C993, 1999.
27. O'Brien SF, McKendrick JD, Radomski MW, Davidge ST, Russell JC. Vascular wall reactivity in conductance and resistance arteries: differential effects of insulin resistance. Can J Physiol Pharmacol 76: 72-76, 1998.
28. O'Brien SF, Russell JC, Dolphin PJ, Davidge ST. Vascular wall function in insulin-resistant JCR: LA-cp rats: role of male and female sex. J Cardiovasc Pharmacol 36: 176-181, 2000.
29. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L, Wang L, Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298-1305, 2005.
30. Pagotto U, Cervino C, Vicennati V, Marsicano G, Lutz B, Pasquali R. How many sites of action for endocannabinoids to control energy metabolism? Int J Obes (Lond) 30: S39-S43, 2006.
31. Pierce WD, Heth CD, Owczarczyk JC, Russell JC, Proctor SD. Overeating by young obesity-prone and lean rats caused by tastes associated with low energy foods. Obesity (Silver Spring) 15: 1969-1979, 2007.
32. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761-775, 2006.
33. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, Janiak P, Herbert JM. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7: 65-72, 2005.
34. Proctor SD, Kelly SE, Stanhope KL, Havel PJ, Russell JC. Synergistic effects of conjugated linoleic acid and chromium picolinate improve vascular function and renal pathophysiology in the insulin-resistant JCR: LA-cp rat. Diabetes Obes Metab 9: 87-95, 2007.
35. Proctor SD, Russell JC. Small animal models of cardiovascular disease: tools for study of roles of the metabolic syndrome, dyslipidemias and atherosclerosis. Cardiovasc Pathol 15: 318-330, 2006.
36. Proctor SD, Vine DF, Mamo JC. Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy. Arterioscler Thromb Vasc Biol 24: 2162-2167, 2004.
37. Richardson M, Schmidt AM, Graham SE, Achen B, DeReske M, Russell JC. Vasculopathy and insulin resistance in the JCR:LA-cp rat. Atherosclerosis 138: 135-146, 1998.
38. Ritchie SA, Connell JMC. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 17: 319-326, 2007.
39. Russell JC, Amy RM. Plasma lipids and other factors in the LA/N corpulent rat in the presence of chronic exercise and food restriction. Can J Physiol Pharmacol 64: 750-756, 1986.
40. Russell JC, Amy RM, Graham SE, Dolphin PJ, Wood GO, Bar-Tana J. Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by 3,3′-tetramethyl hexadecanedioic acid (MEDICA 16). Arterioscler Thromb Vasc Biol 15: 918-923, 1995.
41. Russell JC, Dolphin PJ, Graham SE, Amy RM, Brindley DN. Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine. Diabetologia 41: 380-389, 1998.
42. Russell JC, Graham SE, Amy RM, Dolphin PJ. Inhibition of myocardial lesions in the JCR:LA-corpulent rat by captopril. J Cardiovasc Pharmacol 31: 971-977, 1998.
43. Russell JC, Graham SE, Dolphin PJ. Glucose tolerance and insulin resistance in the JCR:LA-cp rat: effect of miglitol (Bay m1099). Metabolism 48: 701-706, 1999.
44. Russell JC, Graham SE, Richardson M. Cardiovascular disease in the JCR:LA-cp rat. Mol Cell Biochem 188: 113-126, 1998.
45. Russell JC, Kelly SE, Shäfer S. Insulin-sensitizing and cardiovascular effects of the sodium-hydrogen exchange inhibitor, cariporide, in the JCR:LA-cp rat. J Cardiovasc Pharmacol 46: 746-753, 2005.
46. Russell JC, Koeslag DG, Amy RM, Dolphin PJ. Plasma lipid secretion and clearance in the hyperlipidemic JCR:LA-corpulent rat. Arteriosclerosis 9: 869-876, 1989.
47. Russell JC, Koeslag DG, Manickavel V, Amy RM, Dolphin PJ. Effects of advancing age and severe food restriction on pathological processes in the insulin resistant JCR:LA-corpulent rat. Diabetes Res 15: 53-62, 1990.
48. Russell JC, McKendrick JD, Dubé GP, Dolphin PJ, Radomski MW. Effects of LY117018 and the estrogen analogue, 17-ethinylestradiol, on vascular reactivity, platelet aggregation, and lipid metabolism in the insulin-resistant JCR:LA-cp rat: role of nitric oxide. J Cardiovasc Pharmacol 37: 119-128, 2001.
49. Russell JC, Proctor SD. 2-Deoxy-D-glucose mediated increased insulin sensitivity and reduced micro and macro vascular disease of metabolic syndrome in the obese JCR:LA-cp rat. Br J Pharmacol 151: 216-225, 2007.
50. Russell JC, Ravel D, Pégorier JP, Delrat P, Jochemsen R, O'Brien SF, Kelly SE, Davidge ST, Brindley DN. Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat. J Pharmacol Exp Ther 295: 753-760, 2000.
51. Russell JC. The atherosclerosis-prone JCR:LA-corpulent rat. In: Atherosclerosis X: Proceedings of the 10th International Symposium on Atherosclerosis, edited by Woodford FP, Davignon J, and Sniderman A. Amsterdam: Elsevier, 1995, p. 121-125.
52. Russell JC, Kelly SE, Proctor SD. The JCR:LA-cp rat: an animal model of the metabolic syndrome exhibiting micro- and macro-vascular disease. In: Animal Models of Diabetes, edited by Shafrir E. Baton Rouge, LA: CRC, 2007, p. 159-183.
53. Ryan DH. Recent progress in obesity pharmacology. Curr Opin Gastroenterol 16: 166-172, 2002.
54. Schäfer S, Steioff K, Linz W, Bleich M, Busch AE, Löhn M. Chronic vasopeptidase inhibition normalizes diabetic endothelial dysfunction. Eur J Pharmacol 484: 361-362, 2004.
55. Schepers A, Eefting D, Bonta PI, Grimbergen JM, de Vries MR, van Weel V, de Vries CJ, Egashira K, van Bockel JH, Quax PH. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol 26: 2063-2069, 2006.
56. Schneider DJ, Absher PM, Neimane D, Russell JC, Sobel BE. Fibrinolysis and atherogenesis in the JCR:LA-cp rat in relation to insulin and triglyceride concentrations in blood. Diabetologia 41: 141-147, 1998.
57. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients. J Diabetes Complications 20: 98-104, 2006.
58. Turgeon N, Valiquette C, Blais M, Routhier S, Seidman EG, Asselin C. Regulation of C/EBP delta-dependent transactivation by histone deacetylases in intestinal epithelial cells. J Cell Biochem 103: 1573-1583, 2008.
59. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, RIO Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet 365: 1389-1397, 2005. (Pubitemid 40523733)
60. Vance JE, Russell JC. Hypersecretion of VLDL, but not HDL, by hepatocytes from the JCR:LA-corpulent rat. J Lipid Res 31: 1491-1501, 1990.
61. Vine D, Takechi R, Russell JC, Proctor SD. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis 190: 282-290, 2007.
62. Vine DF, Croft KD, Beilin LJ, Mamo JC. Absorption of dietary cholesterol oxidation products and incorporation into rat lymph chylomicrons. Lipids 32: 887-893, 1997.
63. Vine DF, Glimm DR, Proctor SD. Intestinal lipid transport and chylomicron production: possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome. Atheroscler Suppl 9: 69-76, 2008.
64. Wierzbicki AS. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract 60: 1697-1706, 2006.
65. Wu-Peng XS, Chua SC, Okada N, Liu SM, Nicholson M, Leibel RL. Phenotype of the obese Koletsky (f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor (Lepr): evidence for deficient plasma-to-CSF transport of leptin in both the Zucker and Koletsky obese rat. Diabetes 46: 513-518, 1997.
66. Yusuf S, Reddy S, Ôunpuu S, Anand S Global burden of cardiovascular diseases. I. General considerations, the epidemiological transition, risk factors, and impact of urbanization. Circulation 104: 2746-2753, 2001.